Myriad Genetics, Inc. (MYGN)
ROA
Obliczenia
|
2022/Q4 (31 gru 2022) |
2022/Q3 (30 wrz 2022) |
2022/Q2 (30 cze 2022) |
2022/Q1 (31 mar 2022) |
2021/Q4 (31 gru 2021) |
2021/Q3 (30 wrz 2021) |
2021/Q2 (30 cze 2021) |
2021/Q1 (31 mar 2021) |
||
|---|---|---|---|---|---|---|---|---|---|
| Zysk netto (ttm) | w tys. USD | -112 000 | -77 300 | -17 600 | -8 200 | -27 200 | -34 800 | -114 800 | -225 300 |
| Aktywa razem | w tys. USD | 1 198 700 | 1 212 000 | 1 210 200 | 1 255 400 | 1 320 700 | 1 335 900 | 1 360 300 | 1 336 900 |
| ROA | -9,34% | -6,38% | -1,45% | -0,65% | -2,06% | -2,60% | -8,44% | -16,85% |
2022/Q4 obliczenia
ROA = Zysk netto (ttm) ÷ Aktywa razem
= $-112 000K ÷ $1 198 700K
= -9,34%
Analiza porównawcza
2022/Q4
Nazwa spółki
Symbol
ROA
Myriad Genetics, Inc.
MYGN
-9,34%
Amphastar Pharmaceuticals Inc
AMPH
12,32%
Arcus Biosciences Inc
RCUS
-19,85%
Corcept Therapeutics Inc
CORT
17,38%
Dynavax Technologies Corp.
DVAX
29,71%
Harmony Biosciences Holdings Inc
HRMY
26,93%
Ironwood Pharmaceuticals Inc
IRWD
15,91%
Pacira BioSciences Inc
PCRX
0,95%
Supernus Pharmaceuticals Inc
SUPN
2,22%
Xencor Inc
XNCR
-6,52%